Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
You may also be interested in...
Pfizer’s experience in piloting an approach to using US FDA’s Sentinel data network for post-market research demonstrated the feasibility and benefits of doing so.
FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.
Get applications in right, or get a complete response letter, FDA says; firms will have fewer opportunities for mid-review application corrections as review goals reach 10 months.